Hemophilia laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Simrat Sarai (talk | contribs) No edit summary |
|||
| (32 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hemophilia}} | {{Hemophilia}} | ||
{{CMG}};{{AE}} {{Sab}} | |||
==Overview== | |||
== | [[Medical laboratory|Laboratory]] findings consistent with the [[diagnosis]] of hemophilia include normal [[prothrombin time (PT)]], prolonged [[Activated partial thromboplastin time|activated partial thromboplastin time (aPTT)]], [[Prothrombin time|prolonged]] [[Bleeding time|bleeding time (BT)]], and normal [[platelet count]]. | ||
| | ==Laboratory Findings== | ||
| | [[Medical laboratory|Laboratory]] findings consistent with the [[diagnosis]] of hemophilia include: | ||
| | *Normal [[Prothrombin time|prothrombin time (PT)]]<ref name="pmid30129541">{{cite journal |vauthors=Sachdeva A, Gunasekaran V, Ramya HN, Dass J, Kotwal J, Seth T, Das S, Garg K, Kalra M, Sirisha RS, Prakash A |title=Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia |journal=Indian Pediatr |volume=55 |issue=7 |pages=582–590 |date=July 2018 |pmid=30129541 |doi= |url=}}</ref><ref name="pmid17605969">{{cite journal |vauthors=Kamal AH, Tefferi A, Pruthi RK |title=How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults |journal=Mayo Clin. Proc. |volume=82 |issue=7 |pages=864–73 |date=July 2007 |pmid=17605969 |doi=10.4065/82.7.864 |url=}}</ref><ref>https://www.cdc.gov/ncbddd/hemophilia/diagnosis.html</ref><ref name="pmid29780157">{{cite journal |vauthors=Ghozlani I, Mounach A, Ghazi M, Kherrab A, Niamane R |title=Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature |journal=Am J Case Rep |volume=19 |issue= |pages=582–588 |date=May 2018 |pmid=29780157 |pmc=5993004 |doi=10.12659/AJCR.908854 |url=}}</ref> | ||
| | *Normal [[platelet]] count<ref name="pmid30568085">{{cite journal |vauthors=Asai H, Shirayama R, Oshida K, Honda Y, Sato T, Sakai M, Kusuhara K |title=[A Pediatric Case of Acquired Hemophilia A: The Usefulness of the Activated Partial Thromboplastin Time (APTT) Cross-Mixing Test for Early Diagnosis] |language=Japanese |journal=J. UOEH |volume=40 |issue=4 |pages=331–337 |date=2018 |pmid=30568085 |doi=10.7888/juoeh.40.331 |url=}}</ref> | ||
| | *Reduced [[Red blood cell|red blood cell (RBC)]] count and hemoglobin level<ref>Centers for Disease Control and Prevention. Hemophilia Diagnosis. http://www.cdc.gov/ncbddd/hemophilia/diagnosis.html</ref><ref name="pmid30651844">{{cite journal |vauthors=Xu L, Chen J, Zhou X, Wu L, Tong Y, Zhu N, Huang X, Zhang Z |title=Acquired hemophilia A presenting as progressive intra-abdominal hemorrhage, muscle hemorrhage and hemothorax postpartum: A case report and literature review |journal=Exp Ther Med |volume=17 |issue=1 |pages=633–638 |date=January 2019 |pmid=30651844 |pmc=6307365 |doi=10.3892/etm.2018.7031 |url=}}</ref> | ||
| | *Prolonged [[Bleeding time|bleeding time (BT)]]<ref name="pmid3753724">{{cite journal |vauthors=Stuart MJ, Walenga RW, Sadowitz PD, Maltby A, Kelton JG, Gauldie J |title=Bleeding time in hemophilia A: potential mechanisms for prolongation |journal=J. Pediatr. |volume=108 |issue=2 |pages=215–8 |date=February 1986 |pmid=3753724 |doi= |url=}}</ref><ref name="pmid6791725">{{cite journal |vauthors=Eyster ME, Gordon RA, Ballard JO |title=The bleeding time is longer than normal in hemophilia |journal=Blood |volume=58 |issue=4 |pages=719–23 |date=October 1981 |pmid=6791725 |doi= |url=}}</ref> | ||
| | *Elevated [[Activated partial thromboplastin time|activated partial thromboplastin time (aPTT)]]<ref name="pmid30129541">{{cite journal |vauthors=Sachdeva A, Gunasekaran V, Ramya HN, Dass J, Kotwal J, Seth T, Das S, Garg K, Kalra M, Sirisha RS, Prakash A |title=Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia |journal=Indian Pediatr |volume=55 |issue=7 |pages=582–590 |date=July 2018 |pmid=30129541 |doi= |url=}}</ref><ref name="pmid17605969">{{cite journal |vauthors=Kamal AH, Tefferi A, Pruthi RK |title=How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults |journal=Mayo Clin. Proc. |volume=82 |issue=7 |pages=864–73 |date=July 2007 |pmid=17605969 |doi=10.4065/82.7.864 |url=}}</ref><ref name="pmid30568085">{{cite journal |vauthors=Asai H, Shirayama R, Oshida K, Honda Y, Sato T, Sakai M, Kusuhara K |title=[A Pediatric Case of Acquired Hemophilia A: The Usefulness of the Activated Partial Thromboplastin Time (APTT) Cross-Mixing Test for Early Diagnosis] |language=Japanese |journal=J. UOEH |volume=40 |issue=4 |pages=331–337 |date=2018 |pmid=30568085 |doi=10.7888/juoeh.40.331 |url=}}</ref><ref>https://www.cdc.gov/ncbddd/hemophilia/diagnosis.html</ref><ref name="pmid30473893">{{cite journal |vauthors=Gamage M, Weerasinghe S, Nasoor M, Karunarathne AMPW, Abeyrathne SP |title=Progressive Intramuscular Haematoma in a 12-Year-Old Boy: A Case of Acquired Haemophilia A |journal=Case Rep Hematol |volume=2018 |issue= |pages=6208597 |date=2018 |pmid=30473893 |pmc=6220402 |doi=10.1155/2018/6208597 |url=}}</ref><ref name="pmid29780157">{{cite journal |vauthors=Ghozlani I, Mounach A, Ghazi M, Kherrab A, Niamane R |title=Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature |journal=Am J Case Rep |volume=19 |issue= |pages=582–588 |date=May 2018 |pmid=29780157 |pmc=5993004 |doi=10.12659/AJCR.908854 |url=}}</ref> | ||
| | *Bethesda assay indicating the presence of [[antibodies]] against [[factor VIII]]<ref name="pmid30653138">{{cite journal |vauthors=Qian L, Ge H, Hu P, Zhu N, Chen J, Shen J, Zhang Y |title=Pregnancy-related acquired hemophilia A initially manifesting as pleural hemorrhage: A case report |journal=Medicine (Baltimore) |volume=98 |issue=3 |pages=e14119 |date=January 2019 |pmid=30653138 |doi=10.1097/MD.0000000000014119 |url=}}</ref><ref name="pmid23546724">{{cite journal |vauthors=Duncan E, Collecutt M, Street A |title=Nijmegen-Bethesda assay to measure factor VIII inhibitors |journal=Methods Mol. Biol. |volume=992 |issue= |pages=321–33 |date=2013 |pmid=23546724 |doi=10.1007/978-1-62703-339-8_24 |url=}}</ref> | ||
| | *Normal [[fibrinogen]] level<ref name="pmid29780157">{{cite journal |vauthors=Ghozlani I, Mounach A, Ghazi M, Kherrab A, Niamane R |title=Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature |journal=Am J Case Rep |volume=19 |issue= |pages=582–588 |date=May 2018 |pmid=29780157 |pmc=5993004 |doi=10.12659/AJCR.908854 |url=}}</ref><ref name="pmid30568085">{{cite journal |vauthors=Asai H, Shirayama R, Oshida K, Honda Y, Sato T, Sakai M, Kusuhara K |title=[A Pediatric Case of Acquired Hemophilia A: The Usefulness of the Activated Partial Thromboplastin Time (APTT) Cross-Mixing Test for Early Diagnosis] |language=Japanese |journal=J. UOEH |volume=40 |issue=4 |pages=331–337 |date=2018 |pmid=30568085 |doi=10.7888/juoeh.40.331 |url=}}</ref> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
{| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|} | |||
==References== | ==References== | ||
| Line 76: | Line 22: | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Neonatology]] | [[Category:Neonatology]] | ||
Latest revision as of 19:29, 31 May 2019
|
Hemophilia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemophilia laboratory findings On the Web |
|
American Roentgen Ray Society Images of Hemophilia laboratory findings |
|
Risk calculators and risk factors for Hemophilia laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]
Overview
Laboratory findings consistent with the diagnosis of hemophilia include normal prothrombin time (PT), prolonged activated partial thromboplastin time (aPTT), prolonged bleeding time (BT), and normal platelet count.
Laboratory Findings
Laboratory findings consistent with the diagnosis of hemophilia include:
- Normal prothrombin time (PT)[1][2][3][4]
- Normal platelet count[5]
- Reduced red blood cell (RBC) count and hemoglobin level[6][7]
- Prolonged bleeding time (BT)[8][9]
- Elevated activated partial thromboplastin time (aPTT)[1][2][5][10][11][4]
- Bethesda assay indicating the presence of antibodies against factor VIII[12][13]
- Normal fibrinogen level[4][5]
References
- ↑ 1.0 1.1 Sachdeva A, Gunasekaran V, Ramya HN, Dass J, Kotwal J, Seth T, Das S, Garg K, Kalra M, Sirisha RS, Prakash A (July 2018). "Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia". Indian Pediatr. 55 (7): 582–590. PMID 30129541.
- ↑ 2.0 2.1 Kamal AH, Tefferi A, Pruthi RK (July 2007). "How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults". Mayo Clin. Proc. 82 (7): 864–73. doi:10.4065/82.7.864. PMID 17605969.
- ↑ https://www.cdc.gov/ncbddd/hemophilia/diagnosis.html
- ↑ 4.0 4.1 4.2 Ghozlani I, Mounach A, Ghazi M, Kherrab A, Niamane R (May 2018). "Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature". Am J Case Rep. 19: 582–588. doi:10.12659/AJCR.908854. PMC 5993004. PMID 29780157.
- ↑ 5.0 5.1 5.2 Asai H, Shirayama R, Oshida K, Honda Y, Sato T, Sakai M, Kusuhara K (2018). "[A Pediatric Case of Acquired Hemophilia A: The Usefulness of the Activated Partial Thromboplastin Time (APTT) Cross-Mixing Test for Early Diagnosis]". J. UOEH (in Japanese). 40 (4): 331–337. doi:10.7888/juoeh.40.331. PMID 30568085.
- ↑ Centers for Disease Control and Prevention. Hemophilia Diagnosis. http://www.cdc.gov/ncbddd/hemophilia/diagnosis.html
- ↑ Xu L, Chen J, Zhou X, Wu L, Tong Y, Zhu N, Huang X, Zhang Z (January 2019). "Acquired hemophilia A presenting as progressive intra-abdominal hemorrhage, muscle hemorrhage and hemothorax postpartum: A case report and literature review". Exp Ther Med. 17 (1): 633–638. doi:10.3892/etm.2018.7031. PMC 6307365. PMID 30651844.
- ↑ Stuart MJ, Walenga RW, Sadowitz PD, Maltby A, Kelton JG, Gauldie J (February 1986). "Bleeding time in hemophilia A: potential mechanisms for prolongation". J. Pediatr. 108 (2): 215–8. PMID 3753724.
- ↑ Eyster ME, Gordon RA, Ballard JO (October 1981). "The bleeding time is longer than normal in hemophilia". Blood. 58 (4): 719–23. PMID 6791725.
- ↑ https://www.cdc.gov/ncbddd/hemophilia/diagnosis.html
- ↑ Gamage M, Weerasinghe S, Nasoor M, Karunarathne A, Abeyrathne SP (2018). "Progressive Intramuscular Haematoma in a 12-Year-Old Boy: A Case of Acquired Haemophilia A". Case Rep Hematol. 2018: 6208597. doi:10.1155/2018/6208597. PMC 6220402. PMID 30473893. Vancouver style error: initials (help)
- ↑ Qian L, Ge H, Hu P, Zhu N, Chen J, Shen J, Zhang Y (January 2019). "Pregnancy-related acquired hemophilia A initially manifesting as pleural hemorrhage: A case report". Medicine (Baltimore). 98 (3): e14119. doi:10.1097/MD.0000000000014119. PMID 30653138.
- ↑ Duncan E, Collecutt M, Street A (2013). "Nijmegen-Bethesda assay to measure factor VIII inhibitors". Methods Mol. Biol. 992: 321–33. doi:10.1007/978-1-62703-339-8_24. PMID 23546724.